14:27 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on solid tumor indications where it sees larger market...
20:59 , Jun 25, 2018 |  BC Extra  |  Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on...
17:22 , Apr 20, 2018 |  BC Week In Review  |  Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain rights...
20:15 , Apr 16, 2018 |  BC Extra  |  Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain rights...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
18:34 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA accepts BLA for Shire's enzyme replacement for ALL

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review its BLA for calaspargase pegol (Cal-PEG; SHP663) as part of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia in a first-line setting. Its PDUFA date...
19:04 , Feb 28, 2018 |  BC Extra  |  Company News

FDA reviewing Shire's enzyme replacement for ALL

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review its BLA for calaspargase pegol (Cal-PEG; SHP663) as part of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia in a first-line setting. Its PDUFA date...
19:16 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest depleting asparagine with l-asparaginase or ASNS inhibition could help treat metastatic breast cancer. In an allogeneic mouse model of metastatic breast cancer, shRNA targeting ASNS decreased the number of lung...
17:13 , Dec 14, 2017 |  BC Week In Review  |  Clinical News

Erytech's Graspa misses in Phase IIb AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia (AML) in patients ineligible for...
23:44 , Dec 8, 2017 |  BC Extra  |  Clinical News

Erytech sinks after Graspa miss in AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia in...